B. Riley decreased their FY2024 earnings estimates for Novavax in a report issued on Thursday, February 20th. B. Riley ...

Researchers from the Wuhan Institute of Virology in China have discovered a new strain of the coronavirus in bats, which ...

Lab experiments showed that the virus could infect human cells with high ACE2 levels, including models of human intestines ...

The bat virus HKU5-CoV-2 contains a feature known as the furin cleavage site that helps it to enter cells via the ACE2 receptor protein on cell surfaces ...

Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday.

Bullish option flow detected in Novavax (NVAX) with 23,789 calls trading, 3x expected, and implied vol increasing over 8 points to 114.25%.

Shares of Novavax Inc. NVAX slipped 1.25% to $7.92 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.47% to 19,962.

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

The stock's fall snapped a three-day winning streak.

Novavax NVAX is expected to report fourth-quarter and full-year 2024 earnings later this month. In the last reported quarter, ...